Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 10/20 | 0.63 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.47 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4493664 | 0.99 | NSD2 (0.64) | NSD2NPY5RCA12CA9CYP19A1 | |
| Hydrochloric Acid SCHEMBL6909699 | 0.87 | FABP4 (0.51) | NSD2NPY5RCA12CA9L3MBTL1 | |
| SCHEMBL4482603 | 0.86 | NSD2 (0.53) | NSD2NPY5RCYP19A1 | |
| SCHEMBL20026077 | 0.84 | NSD2 (0.70) | NSD2NPY5RCA12CA9KEAP1 | |
| SCHEMBL8913909 | 0.78 | KMT2A (0.66) | NSD2NPY5RLMNAMAPK1 | |
| SCHEMBL14919840 | 0.78 | SLC6A9 (0.43) | LMNAALDH1A1 | |
| SCHEMBL4474391 | 0.78 | NSD2 (0.49) | NSD2NPY5RCA12CA9LMNA | |
| SCHEMBL7457681 | 0.77 | NPY5R (0.64) | NSD2NPY5RCA9ALDH1A1 | |
| SCHEMBL4441197 | 0.77 | NSD2 (1.00) | NSD2NPY5R | |
| SCHEMBL9226619 | 0.77 | PLAU (0.46) | NSD2CA9LMNAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215645-A1 | Amide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2005-09-29 | — | — | US | claimed |
| US-7598418-B2 | Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20050215645-A1 | Amide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215645-A1 | Amide derivatives | OGG1, HDAC1, BCL2A1 | NSD2 639/4885NPY5R 1984/4885CA12 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.